Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Caris Life Sciences, Inc. (CAI)

Caris Life Sciences raises 2026 revenue guidance to $1.04 billion to $1.05 billion

Mixed Impact 4 of 5 guidance Written later

Caris Life Sciences reported third quarter 2026 revenue of $275.4 million, up 27% from a year earlier, and raised its full-year 2026 revenue forecast to $1.04 billion to $1.05 billion. Net income fell to $15.3 million from $24.3 million, and operating cash flow was negative, so shareholders get faster sales growth alongside lower profit and cash generation.

Key points

  • Q3 2026 total revenue was $275.4 million, up from $216.8 million in Q3 2025.
  • Net income was $15.3 million, down from $24.3 million; basic and diluted EPS were $0.05 versus $0.09 and $0.08.
  • Full-year 2026 revenue guidance raised to $1.04 billion to $1.05 billion, growth of 28% to 29%.
  • Net cash used in operating activities was $22.2 million; free cash flow was $(39.7) million.

The filing

CompanyCaris Life Sciences, Inc. (CAI)
Form8-K, current report
Filed with the SECNov 4, 2026, 4:12 PM ET
Accession number0002019410-26-000067

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.